Meningoencephalitis in relapsing polychondritis
A case report

Haruki Matsumoto, MDa, Ryo Tokimura, MDb, Yuya Fujita, MDb, Naoki Matsuoka, MDa, Tomoyuki Asano, MD, PhDa, Shuzo Sato, MD, PhDa, Junpei Temmoku, MDa, Makiko Yashiro-Furuya, MD, PhDa, Kenji Yoshida, MDb, Ryoma Takahashi, MDb, Shoko Tanaka, MDb, Yuya Itagaki, MDb, Mari Honma, MD, PhDc, Nozomu Matsuda, MD, PhDa, Hiroshi Watanabe, MD, PhDa, Kiyoshi Migita, MD, PhDa,*, Kazuaki Kanai, MD, PhDb

Abstract
Rationale: Aseptic meningoencephalitis is a rare central nervous system complication of relapsing polychondritis (RP).
Patient: We report a 61-year-old Japanese male patient with spiking fever and impaired consciousness. Neurological examination revealed meningeal irritation, and cerebrospinal fluid (CSF) examination showed lymphocytic pleocytosis with elevated protein (199 mg/dL) and interleukin-6 (3810 pg/mL). Serological analysis showed high levels of anti-type II collagen antibodies, and the result of auricular biopsy was consistent with the diagnosis of RP showing cartilage degeneration surrounded by inflammatory cell infiltrations.
Diagnosis: A clinical diagnosis of RP was made according to the diagnostic criteria established by MacAdams et al.
Intervention: Steroid pulse therapy (methylprednisolone 1000 mg, consecutive 3 days) followed by oral prednisolone (60 mg/day) resolved the patient’s high fever and disturbance of consciousness.
Outcomes: The patient rapidly improved after steroid treatments and has a normal quality of life under the maintenance dose of steroid plus methotrexate (4 mg/week).
Lessons: RP-associated meningoencephalitis is a rare complication with significant morbidity and mortality. It should be considered and differentiated in patients with RP with unexplained spiking fever and impaired consciousness. In addition, the assessment of cerebrospinal fluid interleukin-6 levels may be useful to investigate the disease activity of RP-related meningoencephalitis. Further prospective studies are required to confirm this result.
Abbreviations: CNS = central nervous system, CSF = cerebrospinal fluid, IL-6 = interleukin-6, MTX = methotrexate, PSL = prednisolone, RP = relapsing polychondritis.
Keywords: anti-type II collagen antibodies, cerebrospinal fluid, interleukin-6, meningoencephalitis, relapsing polychondritis

1. Introduction
Relapsing polychondritis is a rare autoimmune disease characterized by progressive inflammation and destruction of cartilaginous tissues in the ear, nose, and tracheobronchial trees.[1] Although the etiology is unknown, type II collagen is considered a potential autoantigen.[2] This disease has a wide array of clinical...
manifestations that can mimic rheumatic diseases. However, the involvement of the central nervous system (CNS) is rare with diagnostic dilemma.[3] Here we report a patient with impaired consciousness and cerebrospinal fluid (CSF) pleocytosis with suspicion of infectious meningoencephalitis. However, further exploration led to a diagnosis of RP-related meningoencephalitis.

2. Case presentation

A 61-year-old Japanese male patient was referred to our hospital for fever, headache, and confusion. One month before admission, he presented with newly onset fever and headache. A lumbar puncture was performed at that time, and CSF showed a raised protein concentration, pleocytosis, and hypoglycrrachia. Cranial computed tomography (CT) and magnetic resonance imaging (MRI) showed no abnormal findings except for a right parietal lobe lesion due to past head trauma. Initially, infectious meningoencephalitis was suspected, and acyclovir, vancomycin, meropenem, and dexamethasone were administered. Confusional state improved temporarily, and CSF cell count decreased. However, the patient relapsed with delirium and spiking fever. In addition, posterior pain in the left ear appeared. He was transferred to our hospital for further examination.

On admission, the patient’s body temperature was 36.7°C, and his blood pressure was 142/88mmHg. During hospitalization, he had spiking fevers of ≥38°C. A physical examination revealed meningeal irritation and floppy appearance of his left ear (Fig. 1A). He scored 27/30 on the Mini-Mental State Examination, but he then developed recurrent episodes of altered awareness. Occasionally, he was unable to communicate accurately with the medical staff. A neurological examination showed general exaggeration of bilateral deep tendon reflexes and myoclonus of right lower extremity.

Laboratory data showed an inflammatory reaction (Table 1). The patient had an elevated C-reactive protein (CRP) level of 2.09 mg/dL and an elevated erythrocytes sedimentation rate of 70 mm/hr. Antibody to type II collagen was positive with high titers (44.3 EU/mL, <25 EU/mL). The CSF contained 189 cells/μL (mononucleocyte 32.6%, polymorphonuclear cell 47.4%), with a protein level of 199 mg/dL and a glucose level of 36 mg/dL. The oligoclonal bands were negative, but the immunoglobulin G (IgG) index in the CSF was elevated to 1.02. Cultures and polymerase chain reaction testing of the CSF for bacteria, mycobacterium, and herpes simplex viruses were negative. However, the CSF levels of interleukin-6 (IL-6) were significantly elevated (3810 pg/mL). Immunological tests and microbiological tests ruled out other diseases (Table 1). Electroencephalography showed poorly organized posterior dominant rhythm of 8 to 9 Hz and no epileptiform discharges.

Cranial MRI was performed again and fluid-attenuated inversion recovery (FLAIR) images showed diffuse hyperintense signals in cerebral sulci and both auricles (Fig. 2A and B). 18F-FDG positron emission tomography-computed tomography revealed strong accumulation in left auricle (Fig. 3). An ear cartilage biopsy showed moderate infiltration of inflammatory cells (neutrophils) around cartilage tissue (Fig. 4). He was diagnosed with relapsing polychondritis (RP) according to McAdam’s criteria.[4]

The patient was treated with methylprednisolone (mPSL) pulse therapy (1000 mg/d for 3 consecutive days), followed by oral prednisolone (PSL) at a dose of 60 mg/d for 2 weeks. Consequently, his symptoms improved, and oral PSL was gradually tapered. Improvement in cognitive function, other neurological symptoms, and swelling of the auricle were achieved (Fig. 1 B). The high-intensity signals in cerebral surface in the FLAIR images disappeared after the treatment with glucocorticoid therapy (Fig. 2 C and D). The CSF levels of interleukin-6 (IL-6) decreased to 48.8 pg/mL. Methotrexate (MTX) 4 mg per week was introduced when PSL was reduced to 35 mg/day. The patient was discharged, and no relapse occurred at approximately 2 months after treatment.

3. Discussion

Relapsing polychondritis is a rare autoimmune disease characterized by systemic inflammation of cartilaginous structures leading to progressive articular or organ damage.[1] Central nervous system involvement is rare, and only 3% of patients with RP develop neurological involvement related to meningeal inflammation or vasculitis in the CNS.[5–7] We presented a 61-year-old male who presented with RP-related symptoms as well as spiking fever and impaired consciousness. CSF analysis showed pleocytosis and elevated protein levels. All viral, bacterial, and paraneoplastic studies were negative. During the

Figure 1. Changes of ear symptom before and after treatment. (A) Floppy-eared appearance of left ear. (B) After glucocorticoid therapy, redness and swollen of left ear was obviously improved.
clinical course, the patient developed recurrent episodes of altered awareness. MRI showed diffuse FLAIR hyperintense signal throughout cerebral sulci.

This patient presented with subacute encephalopathy mimicking encephalitis or CNS vasculitis. Furthermore, there was no history or findings suggestive of tumor, recent vaccination, or drug or immune-mediated aseptic meningitis. After ruling out these possibilities, the presence of anti-type II collagen antibody led to the diagnosis of RP-related meningoencephalitis.

The etiology of CNS complications in patients with RP remains unknown because of its rarity. Although vasculitis is assumed to be a cause of CNS involvements in RP, brain autopsies performed in patients with RP showed neuronal loss and gliosis with lymphocytic infiltration, suggesting an autoimmune mechanism in its pathogenesis. The patient in this case showed marked pleocytosis with elevated polymorphonuclear cells and markedly elevated levels of IL-6 and IgG in the CSF. CSF analysis in patients with RP with CNS involvement shows abnormalities including pleocytosis and reduced glucose levels that mimic pyogenic meningitis. Therefore, we suspected an autoimmune mechanism in the pathophysiological processes of meningoencephalitis seen in this case.

IL-6 is a critical cytokine in the TIR17 pathway of T cell development in addition to B cell differentiation or antibody production. Previous reports have suggested that IL-6 is involved in the autoimmune encephalitis, because these patients have elevated levels of IL-6 in the CSF. In contrast to these reports, IL-6 is presumed to be purely injurious to the nervous system. The expressions of the autoantigens, such as type II collagen in the basement membrane of parenchymal cerebrovasculature initiate in the leptomeninges and parenchymal cerebrovasculature to provide sites for autoantibody-antigen immune reactions to produce cytokine secretion.

In this patient with RP, IL-6 was markedly elevated in the CSF. Previous studies have shown the therapeutic role for IL-6 blockage in these reported cases.

Given the autoimmunity in the pathogenesis of RP, a number of biologics targeting the cytokine-mediated cascade are being used in patients with RP. Kawai et al have reported satisfactory effects of the anti-interleukin-6 receptor antibody tocilizumab in 2 patients with refractory RP. The positive therapeutic role for IL-6 blockage in these reported cases
Figure 2. Fluid-attenuated inversion recovery images of brain magnetic resonance imaging. (A, B) Diffuse hyperintense signals in cerebral sulci and both auricles. (C, D) After treatment, the high intensity signals disappeared. The lesion in the right parietal lobe is due to past trauma.

Figure 3. Finding of 18F-FDG positron emission tomography-computed tomography (PET-CT). (A) 18F-FDG PET-CT revealed strong accumulation in both auricles. (B) Metabolic activity lesion was corresponded to mild skin thickening on the CT.
suggests that the elevated IL-6 levels in the affected sites and IL-6 inhibition may therefore disrupt cellular and humoral immune pathway contributing to PR and its organ involvement.

We present a case of RP with high fever and decreased consciousness, which can be halted and completely reversed with immunosuppressive treatments. More evidence is required to assess the efficacy of these agents and to identify the role of IL-6 in the immunopathological processes of RP including CNS involvement. Moreover, early recognition of CNS involvement, in addition to cartilage or articular features of RP, is vital to the timely management of RP, thus allowing for the prevention of irreversible brain damage. Given the immunological mechanisms involved in RP, meningoencephalitis lesions in brain may occur. The present case highlights the importance of CSF IL-6 levels in the screening RP-related meningoencephalitis. There are no known optional therapeutic approaches to RP with meningoencephalitis because of its rarity. Usually, steroid therapy including steroid pulse therapy is administered.\[18\] Infectiveness or flare-ups may occur with steroid monotherapy, and therefore, the combination of immunosuppressive agents such as azathioprine, MTX, or cyclophosphamide is needed during the course of steroid therapy.\[19\] In this case, clinical improvement was achieved after combined immunosuppressive treatment consisting of steroid plus MTX.

4. Conclusions

Meningoencephalitis is a rare manifestation of RP. Here, we report a patient with RP with meningoencephalitis with severe brain damage and elevated levels of IL-6 in the CSF. The patient recovered completely with steroid therapy. Early diagnosis and prompt therapeutic intervention are important in RP patients with meningoencephalitis. More cases and research are required to identify the pathological role of IL-6 in this rare neurological involvement of RP.

Acknowledgments

The authors are grateful to Ms Sachiyu Kanno for her technical assistance in this study.

Author contributions

Conceptualization: Haruki Matsumoto, Ryo Tokimura, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Junpei Temmoku, Makiko Yashiro-Furuya, Kenji Yoshida, Ryoma Takahashi, Shoko Tanaka, Yuya Itagaki, Mari Honma, Nozomu Matsuda, Hiroshi Watanabe, Kazuaki Kanai.

Supervision: Kazuaki Kanai, Kiyoshi Migita.

Writing – original draft: Nozomu Matsuda, Haruki Matsumoto, Kiyoshi Migita, Kazuaki Kanai.

Writing – review & editing: Haruki Matsumoto, Kiyoshi Migita.

References

[1] Cantarini L, Vitale A, Brizi MG, et al. Diagnosis and classification of relapsing polychondritis. J Autoimmun 2014;48:53–9.
[2] Arnaud L, Mathian A, Haroche J, et al. Patho genesis of relapsing polychondritis: a 2013 update. Autoimmun Rev 2014;13:90–5.
[3] Zhou A, Li X, Zhao L, et al. Relapsing polychondritis with central nervous system involvement presented as encephalitis: 7 cases and literature review. J Rheum Dis Treat 2017;3:45.
[4] McAdam LP, O’Hanlan MA, Bluestone R, et al. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976;55:193–215.
[5] Hatti K, Giuliano V. Central nervous system involvement in relapsing polychondritis. J Clini Rheumatol 2014;20:396–7.
[6] Erten-Lyons D, Oken B, Woltjer R, et al. Relapsing polychondritis: an uncommon cause of dementia. J Neurol Neurosurg Psychiatry 2008;79:609–10.
[7] Stewart SS, Ashizawa T, Dudley AW, et al. Cerebral vasculitis in relapsing polychondritis. Neurology 1988;38:150–2.
[8] Fujiki F, Tsuoi Y, Hashimoto K, et al. Non-herpetic limbic encephalitis associated with relapsing polychondritis. J Neurol Neurosurg Psychiatry 2004;75:1646–7.
[9] Yang SM, Chou CT. Relapsing polychondritis with encephalitis. J Clini Rheumatol 2004;10:83–5.
[10] Jeon CH. Relapsing polychondritis with central nervous system involvement: experience of three different cases in a single center. J Korean Med Sci 2016;31:1846–50.
[11] Yaguchi H, Tsuzuka K, Nino M, et al. Aseptic meningitis with relapsing polychondritis mimicking bacterial meningitis. Intern Med 2009;48:1841–4.
[12] Kimura A, Naka T, Kishimoto T. IL-6-dependent and independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 2007;104:12099–104.
[13] Shimada K, Koh CS, Yanagisawa N. Detection of interleukin-6 in serum and cerebrospinal fluid of patients with neuroinflammatory diseases. Acta Paediatrica 1995;42:934–40.
[14] Spooren A, Kolmus K, Laureys G, et al. Interleukin-6, a mental cytokine. Brain Res Rev 2011;67:157–83.

[15] Alsalameh S, Mollenhauer J, Scheuplein F, et al. Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. J Rheumatol 1993;20:1419–24.

[16] Moulis G, Pugnet G, Costedoat-Chalamet N, et al. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Ann Rheum Dis 2018;77:1172–8.

[17] Kawai M, Hagihara K, Hirano T, et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford) 2009;48:318–9.

[18] Lahmer T, Treiber M, von Werder A, et al. Relapsing polychondritis: an autoimmune disease with many faces. Autoimmun Rev 2010;9:540–6.

[19] Kingdon J, Roscamp J, Sangle S, et al. Relapsing polychondritis: a clinical review for rheumatologists. Rheumatology (Oxford) 2018;57:1525–32.